A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.
Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research
Jang, H Josh HJ; Hostetter, Galen G; MacFarlane, Alexander W AW; Madaj, Zachary Z; Ross, Eric A EA; Hinoue, Toshinori T; Kulchycki, Justin R JR; Burgos, Ryan S RS; Tafseer, Mahvish M; Alpaugh, R Katherine RK; Schwebel, Candice L CL; Kokate, Rutika R; Geynisman, Daniel M DM; Zibelman, Matthew R MR; Ghatalia, Pooja P; Nichols, Peter W PW; Chung, Woonbok W; Madzo, Jozef J; Hahn, Noah M NM; Quinn, David I DI; Issa, Jean-Pierre J JJ; Topper, Michael J MJ; Baylin, Stephen B SB; Shen, Hui H; Campbell, Kerry S KS; Jones, Peter A PA; Plimack, Elizabeth R ER
Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer.
Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research
Loree, Jonathan M JM; Wang, Yucai Y; Syed, Muddassir A MA; Sorokin, Alexey V AV; Coker, Oluwadara O; Xiu, Joanne J; Weinberg, Benjamin A BA; Vanderwalde, Ari M AM; Tesfaye, Anteneh A; Raymond, Victoria M VM; Miron, Benjamin B; Tarcic, Gabi G; Zelichov, Ori O; Broaddus, Russell R RR; Ng, Patrick Kwok Shing PKS; Jeong, Kang Jin KJ; Tsang, Yiu Huen YH; Mills, Gordon B GB; Overman, Michael J MJ; Grothey, Axel A; Marshall, John L JL; Kopetz, Scott S
Standardization of Somatic Variant Classifications in Solid and Haematological Tumours by a Two-Level Approach of Biological and Clinical Classes: An Initiative of the Belgian ComPerMed Expert Panel.
Cancers
Froyen, Guy G; Le Mercier, Marie M; Lierman, Els E; Vandepoele, Karl K; Nollet, Friedel F; Boone, Elke E; Van der Meulen, Joni J; Jacobs, Koen K; Lambin, Suzan S; Vander Borght, Sara S; Van Valckenborgh, Els E; Antoniou, Aline A; Hébrant, Aline A
Publication Date: 2019-12-16
Variant appearance in text: KRAS: 169G>A; Asp57Asn
Formalin fixation increases deamination mutation signature but should not lead to false positive mutations in clinical practice.
Plos One
Prentice, Leah M LM; Miller, Ruth R RR; Knaggs, Jeff J; Mazloomian, Alborz A; Aguirre Hernandez, Rosalia R; Franchini, Patrick P; Parsa, Kourosh K; Tessier-Cloutier, Basile B; Lapuk, Anna A; Huntsman, David D; Schaeffer, David F DF; Sheffield, Brandon S BS
Identification of Serine 119 as an Effective Inhibitor Binding Site of M. tuberculosis Ubiquitin-like Protein Ligase PafA Using Purified Proteins and M. smegmatis.
Ebiomedicine
Jiang, He-Wei HW; Czajkowsky, Daniel M DM; Wang, Tao T; Wang, Xu-De XD; Wang, Jia-Bin JB; Zhang, Hai-Nan HN; Liu, Cheng-Xi CX; Wu, Fan-Lin FL; He, Xiang X; Xu, Zhao-Wei ZW; Chen, Hong H; Guo, Shu-Juan SJ; Li, Yang Y; Bi, Li-Jun LJ; Deng, Jiao-Yu JY; Xie, Jin J; Pei, Jian-Feng JF; Zhang, Xian-En XE; Tao, Sheng-Ce SC
Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets.
Leukemia
Karube, K K; Enjuanes, A A; Dlouhy, I I; Jares, P P; Martin-Garcia, D D; Nadeu, F F; Ordóñez, G R GR; Rovira, J J; Clot, G G; Royo, C C; Navarro, A A; Gonzalez-Farre, B B; Vaghefi, A A; Castellano, G G; Rubio-Perez, C C; Tamborero, D D; Briones, J J; Salar, A A; Sancho, J M JM; Mercadal, S S; Gonzalez-Barca, E E; Escoda, L L; Miyoshi, H H; Ohshima, K K; Miyawaki, K K; Kato, K K; Akashi, K K; Mozos, A A; Colomo, L L; Alcoceba, M M; Valera, A A; Carrió, A A; Costa, D D; Lopez-Bigas, N N; Schmitz, R R; Staudt, L M LM; Salaverria, I I; López-Guillermo, A A; Campo, E E
Pan-urologic cancer genomic subtypes that transcend tissue of origin.
Nature Communications
Chen, Fengju F; Zhang, Yiqun Y; Bossé, Dominick D; Lalani, Aly-Khan A AA; Hakimi, A Ari AA; Hsieh, James J JJ; Choueiri, Toni K TK; Gibbons, Don L DL; Ittmann, Michael M; Creighton, Chad J CJ
Detection of oncogenic mutations in resected bronchial margins by next-generation sequencing indicates early relapse in stage IA lung adenocarcinoma patients.
Exome Sequencing Identifies Potentially Druggable Mutations in Nasopharyngeal Carcinoma.
Scientific Reports
Chow, Yock Ping YP; Tan, Lu Ping LP; Chai, San Jiun SJ; Abdul Aziz, Norazlin N; Choo, Siew Woh SW; Lim, Paul Vey Hong PV; Pathmanathan, Rajadurai R; Mohd Kornain, Noor Kaslina NK; Lum, Chee Lun CL; Pua, Kin Choo KC; Yap, Yoke Yeow YY; Tan, Tee Yong TY; Teo, Soo Hwang SH; Khoo, Alan Soo-Beng AS; Patel, Vyomesh V
Mutational landscape reflects the biological continuum of plasma cell dyscrasias.
Blood Cancer Journal
Rossi, A A; Voigtlaender, M M; Janjetovic, S S; Thiele, B B; Alawi, M M; März, M M; Brandt, A A; Hansen, T T; Radloff, J J; Schön, G G; Hegenbart, U U; Schönland, S S; Langer, C C; Bokemeyer, C C; Binder, M M
LowMACA: exploiting protein family analysis for the identification of rare driver mutations in cancer.
Bmc Bioinformatics
Melloni, Giorgio E M GE; de Pretis, Stefano S; Riva, Laura L; Pelizzola, Mattia M; Céol, Arnaud A; Costanza, Jole J; Müller, Heiko H; Zammataro, Luca L
Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma.
Bmc Cancer
Kim, Eun Young EY; Cho, Eun Na EN; Park, Heae Surng HS; Kim, Arum A; Hong, Ji Young JY; Lim, Seri S; Youn, Jong Pil JP; Hwang, Seung Yong SY; Chang, Yoon Soo YS